138 related articles for article (PubMed ID: 12964011)
1. A3 adenosine receptor agonist potentiates natural killer cell activity.
Harish A; Hohana G; Fishman P; Arnon O; Bar-Yehuda S
Int J Oncol; 2003 Oct; 23(4):1245-9. PubMed ID: 12964011
[TBL] [Abstract][Full Text] [Related]
2. A novel adenosine analog, thio-Cl-IB-MECA, induces G0/G1 cell cycle arrest and apoptosis in human promyelocytic leukemia HL-60 cells.
Lee EJ; Min HY; Chung HJ; Park EJ; Shin DH; Jeong LS; Lee SK
Biochem Pharmacol; 2005 Sep; 70(6):918-24. PubMed ID: 16051194
[TBL] [Abstract][Full Text] [Related]
3. A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition.
Madi L; Bar-Yehuda S; Barer F; Ardon E; Ochaion A; Fishman P
J Biol Chem; 2003 Oct; 278(43):42121-30. PubMed ID: 12865431
[TBL] [Abstract][Full Text] [Related]
4. Cl-IB-MECA inhibits human thyroid cancer cell proliferation independently of A3 adenosine receptor activation.
Morello S; Petrella A; Festa M; Popolo A; Monaco M; Vuttariello E; Chiappetta G; Parente L; Pinto A
Cancer Biol Ther; 2008 Feb; 7(2):278-84. PubMed ID: 18059189
[TBL] [Abstract][Full Text] [Related]
5. Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist.
Fishman P; Bar-Yehuda S; Ardon E; Rath-Wolfson L; Barrer F; Ochaion A; Madi L
Anticancer Res; 2003; 23(3A):2077-83. PubMed ID: 12894581
[TBL] [Abstract][Full Text] [Related]
6. Effects of synthetic A3 adenosine receptor agonists on cell proliferation and viability are receptor independent at micromolar concentrations.
Mlejnek P; Dolezel P; Frydrych I
J Physiol Biochem; 2013 Sep; 69(3):405-17. PubMed ID: 23184730
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cell proliferation through cell cycle arrest and apoptosis by thio-Cl-IB-MECA, a novel A3 adenosine receptor agonist, in human lung cancer cells.
Kim SJ; Min HY; Chung HJ; Park EJ; Hong JY; Kang YJ; Shin DH; Jeong LS; Lee SK
Cancer Lett; 2008 Jun; 264(2):309-15. PubMed ID: 18321638
[TBL] [Abstract][Full Text] [Related]
8. Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells.
Fishman P; Madi L; Bar-Yehuda S; Barer F; Del Valle L; Khalili K
Oncogene; 2002 Jun; 21(25):4060-4. PubMed ID: 12037688
[TBL] [Abstract][Full Text] [Related]
9. IB-MECA, an A3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis.
Rath-Wolfson L; Bar-Yehuda S; Madi L; Ochaion A; Cohen S; Zabutti A; Fishman P
Clin Exp Rheumatol; 2006; 24(4):400-6. PubMed ID: 16956430
[TBL] [Abstract][Full Text] [Related]
10. The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis.
Fishman P; Bar-Yehuda S; Madi L; Rath-Wolfson L; Ochaion A; Cohen S; Baharav E
Arthritis Res Ther; 2006; 8(1):R33. PubMed ID: 16507132
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein mediates resistance to A3 adenosine receptor agonist 2-chloro-N6-(3-iodobenzyl)-adenosine-5'-n-methyluronamide in human leukemia cells.
Mlejnek P; Dolezel P; Kosztyu P
J Cell Physiol; 2012 Feb; 227(2):676-85. PubMed ID: 21520073
[TBL] [Abstract][Full Text] [Related]
12. The adenosine A3 receptor agonist Cl-IB-MECA induces cell death through Ca²⁺/ROS-dependent down regulation of ERK and Akt in A172 human glioma cells.
Kim TH; Kim YK; Woo JS
Neurochem Res; 2012 Dec; 37(12):2667-77. PubMed ID: 22878643
[TBL] [Abstract][Full Text] [Related]
13. A3 adenosine receptor agonist induce G1 cell cycle arrest via Cyclin D and cyclin-dependent kinase 4 pathways in OVCAR-3 and Caov-4 cell lines.
Joshaghani HR; Jafari SM; Aghaei M; Panjehpour M; Abedi H
J Cancer Res Ther; 2017; 13(1):107-112. PubMed ID: 28508842
[TBL] [Abstract][Full Text] [Related]
14. Suppression of inflammation response by a novel A₃ adenosine receptor agonist thio-Cl-IB-MECA through inhibition of Akt and NF-κB signaling.
Lee HS; Chung HJ; Lee HW; Jeong LS; Lee SK
Immunobiology; 2011 Sep; 216(9):997-1003. PubMed ID: 21514967
[TBL] [Abstract][Full Text] [Related]
15. A3 Adenosine Receptor Agonist Inhibited Survival of Breast Cancer Stem Cells via GLI-1 and ERK1/2 Pathway.
Jafari SM; Panjehpour M; Aghaei M; Joshaghani HR; Enderami SE
J Cell Biochem; 2017 Sep; 118(9):2909-2920. PubMed ID: 28230290
[TBL] [Abstract][Full Text] [Related]
16. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models.
Baharav E; Bar-Yehuda S; Madi L; Silberman D; Rath-Wolfson L; Halpren M; Ochaion A; Weinberger A; Fishman P
J Rheumatol; 2005 Mar; 32(3):469-76. PubMed ID: 15742438
[TBL] [Abstract][Full Text] [Related]
17. The A3 adenosine receptor as a new target for cancer therapy and chemoprotection.
Fishman P; Bar-Yehuda S; Barer F; Madi L; Multani AS; Pathak S
Exp Cell Res; 2001 Oct; 269(2):230-6. PubMed ID: 11570815
[TBL] [Abstract][Full Text] [Related]
18. A3 adenosine receptor as a target for cancer therapy.
Fishman P; Bar-Yehuda S; Madi L; Cohn I
Anticancer Drugs; 2002 Jun; 13(5):437-43. PubMed ID: 12045454
[TBL] [Abstract][Full Text] [Related]
19. Enhancing pigmentation via activation of A3 adenosine receptors in B16 melanoma cells and in human skin explants.
Madi L; Rosenberg-Haggen B; Nyska A; Korenstein R
Exp Dermatol; 2013 Jan; 22(1):74-7. PubMed ID: 23088669
[TBL] [Abstract][Full Text] [Related]
20. The infarct-sparing effect of IB-MECA against myocardial ischemia/reperfusion injury in mice is mediated by sequential activation of adenosine A3 and A 2A receptors.
Tian Y; Marshall M; French BA; Linden J; Yang Z
Basic Res Cardiol; 2015 Mar; 110(2):16. PubMed ID: 25711314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
